Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 3/2015

01-09-2015 | Review Article

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Authors: F. Petrelli, E. Pezzica, M. Cabiddu, A. Coinu, K. Borgonovo, M. Ghilardi, V. Lonati, D. Corti, S. Barni

Published in: Journal of Gastrointestinal Cancer | Issue 3/2015

Login to get access

Abstract

Purpose

Tumour budding is defined as the presence of isolated or small clusters of malignant cells at the invasive edge of the tumour. It is considered a negative prognostic factor in colorectal cancer (CRC) and is associated with a poor outcome and adverse pathological features. Here, we report a meta-analysis of the association of tumour budding and survival in stage II CRC patients.

Methods

PubMed, EMBASE, Web of Science and SCOPUS were searched for studies that assessed the relationship between tumour budding and 5-year overall survival (OS) in stage II CRC patients. Published data were extracted and used to compute odds ratios (ORs) for death at 5 years and hazard ratios (HRs) for survival amongst patients with respect to the extent of tumour budding, using multivariate analysis. Data were pooled using the Mantel–Haenszel random effect model.

Results

We analysed 12 studies that included a total of 1652 patients. High-grade budding was associated with worse OS at 5 years (OR for death, 6.25; 95 % confidence interval [CI], 4.04–9.67; P < 0.00001). The absolute difference in 5-year OS was −25 % (95 % CI, −18– − 33 %, P < 0.00001). It was particularly noteworthy that the presence of high-grade budding was associated with an increased risk of death (HR for death, 3.68; 95 % CI, 2.16–6.28, P < 0.00001).

Conclusions

Tumour budding is associated with worse survival in stage II CRC, in particular in pT3N0M0 patients. It could therefore potentially be used when deciding whether to administer adjuvant chemotherapy in high-risk node negative CRC patients.
Literature
1.
go back to reference Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRef Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRef
2.
go back to reference Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2012;16:646–55.PubMedCrossRef Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2012;16:646–55.PubMedCrossRef
4.
go back to reference Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.PubMedCentralPubMedCrossRef Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.PubMedCentralPubMedCrossRef
5.
go back to reference Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.PubMedCrossRef Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.PubMedCrossRef
6.
go back to reference Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II welldifferentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.PubMedCrossRef Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II welldifferentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.PubMedCrossRef
7.
go back to reference Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.PubMedCrossRef Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.PubMedCrossRef
8.
go back to reference Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.PubMedCrossRef Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.PubMedCrossRef
9.
go back to reference Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.PubMedCrossRef Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.PubMedCrossRef
10.
go back to reference Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651–61.PubMedCentralPubMed Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651–61.PubMedCentralPubMed
11.
go back to reference Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539–43.PubMedCrossRef Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539–43.PubMedCrossRef
12.
go back to reference Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.PubMedCrossRef Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.PubMedCrossRef
13.
go back to reference Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reportingsystematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.PubMedCentralPubMedCrossRef Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reportingsystematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.PubMedCentralPubMedCrossRef
14.
go back to reference Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer. Color Dis. 2014;16(4):259–64.CrossRef Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer. Color Dis. 2014;16(4):259–64.CrossRef
15.
go back to reference Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19(12):3706–12.PubMedCrossRef Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19(12):3706–12.PubMedCrossRef
16.
go back to reference Canney AL, Kevans D, Wang LM, et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology. 2012;61(3):488–96.PubMedCrossRef Canney AL, Kevans D, Wang LM, et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology. 2012;61(3):488–96.PubMedCrossRef
17.
go back to reference Kevans D, Wang LM, Sheahan K, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 2011;19(6):751–60.PubMedCrossRef Kevans D, Wang LM, Sheahan K, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 2011;19(6):751–60.PubMedCrossRef
18.
go back to reference Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46(8):1054–9.PubMedCrossRef Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46(8):1054–9.PubMedCrossRef
19.
go back to reference Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.PubMedCrossRef Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.PubMedCrossRef
20.
go back to reference Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28(3B):1773–8.PubMed Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28(3B):1773–8.PubMed
21.
go back to reference Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48(8):1597–602.PubMedCrossRef Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48(8):1597–602.PubMedCrossRef
22.
go back to reference Choi HJ, Park KJ, Shin JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis. 2007;22:863–8.CrossRef Choi HJ, Park KJ, Shin JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis. 2007;22:863–8.CrossRef
23.
go back to reference Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25:1269–72.PubMed Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25:1269–72.PubMed
24.
go back to reference Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.PubMedCentralPubMedCrossRef Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.PubMedCentralPubMedCrossRef
25.
go back to reference Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.PubMedCrossRef Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.PubMedCrossRef
26.
go back to reference Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol. 2010;102:230–4.PubMedCrossRef Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol. 2010;102:230–4.PubMedCrossRef
27.
go back to reference Kajiwara Y, Ueno H, Hashiguchi Y, et al. Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum. 2010;53:1393–9.PubMedCrossRef Kajiwara Y, Ueno H, Hashiguchi Y, et al. Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum. 2010;53:1393–9.PubMedCrossRef
28.
go back to reference Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Color Dis. 2008;10:41–7. Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Color Dis. 2008;10:41–7.
29.
go back to reference Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.PubMedCentralPubMedCrossRef Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.PubMedCentralPubMedCrossRef
30.
go back to reference Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382–92.PubMedCentralPubMedCrossRef Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382–92.PubMedCentralPubMedCrossRef
31.
go back to reference Masaki T, Matsuoka H, Sugiyama M, et al. Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol. 2005;92:59–63.PubMedCrossRef Masaki T, Matsuoka H, Sugiyama M, et al. Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol. 2005;92:59–63.PubMedCrossRef
32.
go back to reference Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60:912–5.PubMedCentralPubMedCrossRef Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60:912–5.PubMedCentralPubMedCrossRef
33.
go back to reference Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.PubMedCrossRef Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.PubMedCrossRef
34.
go back to reference Ueno H, Murphy J, Jass JR, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.PubMedCrossRef Ueno H, Murphy J, Jass JR, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.PubMedCrossRef
36.
go back to reference Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.PubMedCrossRef Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.PubMedCrossRef
37.
go back to reference Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.PubMedCrossRef Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.PubMedCrossRef
38.
go back to reference Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed
39.
go back to reference Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain an tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.PubMedCrossRef Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain an tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.PubMedCrossRef
40.
go back to reference Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Color Dis. 2011;13:255–62.CrossRef Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Color Dis. 2011;13:255–62.CrossRef
41.
go back to reference Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.PubMedCrossRef Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.PubMedCrossRef
42.
go back to reference Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.PubMedCrossRef Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.PubMedCrossRef
43.
go back to reference Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 2015;21. Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 2015;21.
44.
go back to reference Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.PubMedCrossRef Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.PubMedCrossRef
Metadata
Title
Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis
Authors
F. Petrelli
E. Pezzica
M. Cabiddu
A. Coinu
K. Borgonovo
M. Ghilardi
V. Lonati
D. Corti
S. Barni
Publication date
01-09-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9716-1

Other articles of this Issue 3/2015

Journal of Gastrointestinal Cancer 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.